IE

BEHAVIORAL2 trials

Sponsors

VA Office of Research and Development, Peking University People's Hospital

Conditions

DrugEffect of DrugSchizoaffective DisorderSchizophreniaToxicity

Phase 2

Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)

CompletedNCT05277480

Peking University People's HospitalDrug, Effect of Drug, Toxicity

Start: 2022-03-01End: 2023-11-26Updated: 2024-07-31

Phase 3

Motivational Interviewing to Improve Work Outcomes in Schizophrenia

CompletedNCT00261716

VA Office of Research and DevelopmentSchizoaffective Disorder, Schizophrenia

Start: 2005-01-31End: 2010-02-28Updated: 2016-08-03

Related Papers

Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study.

2025-11-25

Apatinib combined with ifosfamide and etoposide versus ifosfamide and etoposide in relapsed or refractory osteosarcoma (OAIE/PKUPH-sarcoma 11): A multicenter, randomized controlled trial.

Journal of Clinical Oncology2024-06-01